Wockhardt gets US nod for anti-ulcer syrup
MUMBAI, Feb 26 (Reuters) - Drug maker Wockhardt Ltd (WCKH.BO: Quote, Profile, Research) said on Thursday it has secured U.S. Food and Drug Administration approval to sell an alcohol-free syrup of ranitidine hydrochloride, used to treat ulcers and hyper-acidity.
Ranitidine is the generic version of GlaxoSmithKline's (GSK.L: Quote, Profile, Research) Zantac, the company said in a statement.
The U.S. market for the syrup is worth $51 million, the release said.
Wockhardt also said it has secured tentative approval for an alcholol-containing formulation of ranitidine. (Reporting by Bharghavi Nagaraju; editing by Rohini Ananthan)
© Thomson Reuters 2009 All rights reserved
India Investment Summit 2009
Top executives and bankers discuss their own plans and the broader opportunities and challenges for India. Full Coverage
PLAYBOY SALE
An icon bows to changing times
With his Playboy Enterprises in talks to be sold for about $300 million, the 83 year-old Hugh Hefner will be giving up control over the iconic adult entertainment empire he founded that was instrumental in shaping society's opinions on nudity, sex and free speech. Full Article
India
US
UK
